Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Colonic Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gallbladder Neoplasms 1Familial ependymoma 1Colorectal Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 11Cisplatin 9Oxaliplatin 7Leucovorin 6Irinotecan 6Fluorouracil 5Taxes 3Radiotherapy 3Platinum 3Interleukin-12 Subunit p35 3Erlotinib Hydrochloride 3Capecitabine 3Albumin-Bound Paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3Trastuzumab 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2tipifarnib 1sargramostim 1pembrolizumab 1motexafin gadolinium 1merestinib 1guadecitabine 1entinostat 1durvalumab 1dehydroftorafur 1aldesleukin 1Thalidomide 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gallbladder Neoplasms × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

University of Nebraska

Phase 1 Completed
46 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡